Literature DB >> 24792391

Fucoidan attenuates the existing allodynia and hyperalgesia in a rat model of neuropathic pain.

Chuanyin Hu1, Guoping Zhang1, Yun-Tao Zhao2.   

Abstract

Fucoidan is an active constituent found in brown seaweeds, which have potential neuroprotection. The current study aimed to investigate the effects of fucoidan on the maintenance of neuropathic pain induced by L5 spinal nerve ligation (SNL) and the underlying mechanism related to the spinal neuroimmune responses. Animals were randomized into 5 groups: sham-operation with vehicle and SNL with vehicle or fucoidan (15, 50, and 100mg/kg). Different doses of fucoidan or vehicle were administered intrathecally once daily from postoperative day (POD) 11-20. Mechanical withdrawal threshold (MWT) and thermal withdrawal latency (TWL) was measured on 1 day before operation and days 10, 20, 22, 24, 26, 28, 30 after operation. Glial activation markers such as glial fibrillary acidic protein (GFAP) and macrophage antigen complex-1 (mac-1), inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 activation, and extracellular signalregulated protein kinase (ERK) activation in the lumbar spinal cord were determined on day 30 after operation. The results showed that fucoidan caused dose-dependently attenuation of mechanical allodynia and thermal hyperalgesia. Furthermore, fucoidan could markedly inhibit neuroimmune activation characterized by glial activation, production of cytokines as well as ERK activation. The analgesic effect of intrathecal fucoidan in rats receiving SNL might partly attribute to the inhibition of neuroimmune activation associated with the maintenance of neuropathic pain.
Copyright © 2014 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Fucoidan; Neuroimmune activation; Neuropathic pain

Mesh:

Substances:

Year:  2014        PMID: 24792391     DOI: 10.1016/j.neulet.2014.04.030

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  GABAB Receptors and Pain.

Authors:  Dietmar Benke
Journal:  Curr Top Behav Neurosci       Date:  2022

2.  Effect of Bufalin-PLGA Microspheres in the Alleviation of Neuropathic Pain via the CCI Model.

Authors:  Lina Long; Wenwei Zhong; Liwei Guo; Jing Ji; Hong Nie
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

3.  Wnt/beta-Catenin Signaling Contributes to Vincristine-Induced Neuropathic Pain.

Authors:  C Hu; Y-T Zhao; Y-B Cui; H-H Zhang; G-L Huang; Y Liu; Y-F Liu
Journal:  Physiol Res       Date:  2020-06-25       Impact factor: 1.881

4.  The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?

Authors:  Guilherme D Silva; Patrícia S S Lopes; Erich T Fonoff; Rosana L Pagano
Journal:  J Neuroinflammation       Date:  2015-01-20       Impact factor: 8.322

5.  Anti-allodynic effect of Buja in a rat model of oxaliplatin-induced peripheral neuropathy via spinal astrocytes and pro-inflammatory cytokines suppression.

Authors:  Yongjae Jung; Ji Hwan Lee; Woojin Kim; Sang Hyub Yoon; Sun Kwang Kim
Journal:  BMC Complement Altern Med       Date:  2017-01-14       Impact factor: 3.659

Review 6.  Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology.

Authors:  Fernando Pena-Ortega
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

7.  Formulation, Optimization and In Vivo Evaluation of Fucoidan-Based Cream with Anti-Inflammatory Properties.

Authors:  Ekaterina D Obluchinskaya; Olga N Pozharitskaya; Elena V Flisyuk; Alexander N Shikov
Journal:  Mar Drugs       Date:  2021-11-17       Impact factor: 5.118

8.  Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial.

Authors:  Hsiang-Lin Tsai; Chi-Jung Tai; Ching-Wen Huang; Fang-Rong Chang; Jaw-Yuan Wang
Journal:  Mar Drugs       Date:  2017-04-21       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.